UBS raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $46 from $45 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Positive Outlook for Ionis Pharmaceuticals Driven by Strong Q2 Results and Promising Pipeline Developments
- Ionis Pharmaceuticals Reports Strong Earnings and Growth
- Ionis Pharmaceuticals: Hold Rating Amid Strong Performance and Future Uncertainties
- Ionis Pharmaceuticals: Strong Q2 Performance and Promising Future Catalysts Justify Buy Rating
- Ionis Pharmaceuticals price target raised to $65 from $50 at H.C. Wainwright